These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26997447)

  • 1. Expression of liver fatty acid binding protein in hepatocellular carcinoma.
    Cho SJ; Ferrell LD; Gill RM
    Hum Pathol; 2016 Apr; 50():135-9. PubMed ID: 26997447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
    Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
    Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
    Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
    Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA.
    Hechtman JF; Abou-Alfa GK; Stadler ZK; Mandelker DL; Roehrl MHA; Zehir A; Vakiani E; Middha S; Klimstra DS; Shia J
    Hum Pathol; 2019 Jan; 83():1-6. PubMed ID: 30121369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular neoplasms with loss of liver fatty acid binding protein: Clinicopathologic features and molecular profiling.
    Joseph NM; Blank A; Shain AH; Gill RM; Umetsu SE; Shafizadeh N; Torbenson MS; Kakar S
    Hum Pathol; 2022 Apr; 122():60-71. PubMed ID: 35104461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.
    Putra J; Ferrell LD; Gouw ASH; Paradis V; Rishi A; Sempoux C; Balabaud C; Thung SN; Bioulac-Sage P
    Mod Pathol; 2020 Apr; 33(4):665-675. PubMed ID: 31570768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular nodules expressing markers of hepatocellular adenomas in Budd-Chiari syndrome and other rare hepatic vascular disorders.
    Sempoux C; Paradis V; Komuta M; Wee A; Calderaro J; Balabaud C; Quaglia A; Bioulac-Sage P
    J Hepatol; 2015 Nov; 63(5):1173-80. PubMed ID: 26119687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.
    Bioulac-Sage P; Cubel G; Balabaud C; Zucman-Rossi J
    Semin Liver Dis; 2011 Feb; 31(1):91-103. PubMed ID: 21344354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary hepatic tumors with myxoid change: morphologically unique hepatic adenomas and hepatocellular carcinomas.
    Salaria SN; Graham RP; Aishima S; Mounajjed T; Yeh MM; Torbenson MS
    Am J Surg Pathol; 2015 Mar; 39(3):318-24. PubMed ID: 25602798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up.
    Shafizadeh N; Genrich G; Ferrell L; Kakar S
    Hum Pathol; 2014 May; 45(5):976-83. PubMed ID: 24746201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous occurrence of focal nodular hyperplasia and HNF1A-inactivated hepatocellular adenoma: a collision tumor simulating a composite FNH-HCA.
    Shih A; Lauwers GY; Balabaud C; Bioulac-Sage P; Misdraji J
    Am J Surg Pathol; 2015 Sep; 39(9):1296-300. PubMed ID: 26274031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected discovery of small HNF1α-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumours.
    Balabaud C; Laurent C; Le Bail B; Castain C; Possenti L; Frulio N; Chiche L; Blanc JF; Bioulac-Sage P
    Liver Int; 2018 Jul; 38(7):1273-1279. PubMed ID: 29265678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
    Bioulac-Sage P; Rebouissou S; Thomas C; Blanc JF; Saric J; Sa Cunha A; Rullier A; Cubel G; Couchy G; Imbeaud S; Balabaud C; Zucman-Rossi J
    Hepatology; 2007 Sep; 46(3):740-8. PubMed ID: 17663417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
    Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
    Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.
    Kakar S; Grenert JP; Paradis V; Pote N; Jakate S; Ferrell LD
    Mod Pathol; 2014 Nov; 27(11):1499-1509. PubMed ID: 24743216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
    Choi WT; Ramachandran R; Kakar S
    Hum Pathol; 2017 May; 63():1-13. PubMed ID: 28087475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.
    Calderaro J; Labrune P; Morcrette G; Rebouissou S; Franco D; Prévot S; Quaglia A; Bedossa P; Libbrecht L; Terracciano L; Smit GP; Bioulac-Sage P; Zucman-Rossi J
    J Hepatol; 2013 Feb; 58(2):350-7. PubMed ID: 23046672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostains Used to Subtype Hepatic Adenomas Do Not Distinguish Hepatic Adenomas From Hepatocellular Carcinomas.
    Liu L; Shah SS; Naini BV; French S; Wu TT; Torbenson MS; Chandan VS
    Am J Surg Pathol; 2016 Aug; 40(8):1062-9. PubMed ID: 26927891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical stains of proliferating cell nuclear antigen, insulin-like growth factor 2 and clusterin help distinguish malignant from benign liver nodular lesions.
    Lai JP; Chen ZM; Lok T; Chan OT; Himmelfarb E; Zhai Q; Lin F; Wang HL
    J Clin Pathol; 2014 Jun; 67(6):464-9. PubMed ID: 24407433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.